Actithera is built on a proprietary chemistry platform designed to maximize tumor absorbed radiation dose while minimizing off-target exposure. Our approach is isotope-agnostic, enabling flexible pairing of radionuclides based on biological rationale and tumor characteristics. This versatility allows us to target a broad range of cancer indications with precision and purpose.
